Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31045650 | 0.95 | SIGMAR1 (0.47) | SIGMAR1HRH3LMNAALDH1A1CHRM2 | |
| SCHEMBL6615398 | 0.87 | SIGMAR1 (0.51) | SIGMAR1LMNAALDH1A1CHRM2CHRM4 | |
| SCHEMBL6615394 | 0.87 | SIGMAR1 (0.51) | SIGMAR1LMNAALDH1A1CHRM2CHRM4 | |
| SCHEMBL1723411 | 0.84 | CHRM2 (0.58) | SIGMAR1HRH3LMNAALDH1A1CHRM2 | |
| SCHEMBL5728905 | 0.84 | CHRM2 (0.58) | SIGMAR1HRH3LMNAALDH1A1CHRM2 | |
| SCHEMBL4870895 | 0.82 | CHRM2 (0.60) | SIGMAR1HRH3LMNAALDH1A1CHRM2 | |
| SCHEMBL522055 | 0.82 | CYP3A4 (0.52) | SIGMAR1ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL522470 | 0.82 | CYP3A4 (0.52) | SIGMAR1ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL8273913 | 0.82 | CYP3A4 (0.52) | SIGMAR1ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL522054 | 0.82 | CYP3A4 (0.52) | SIGMAR1ALDH1A1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191492-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-3191492-B1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| US-10150766-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-11 | — | — | US | disclosed |
| US-20170342066-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342066-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-20170342066-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| EP-3191492-A1 | P2X7 MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039977-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10150766-B2 | P2X7 modulators | P2RX7, P2RX4, P2RX1 | SIGMAR1 956/4885HRH3 1470/4885LMNA 2334/4885 |
| US-20170342066-A1 | P2X7 MODULATORS | P2RX7, P2RX4, P2RX1 | SIGMAR1 956/4885HRH3 1470/4885LMNA 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.